Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

BRCA1-Dependent Translational Regulation in Breast Cancer Cells.

Dacheux E, Vincent A, Nazaret N, Combet C, Wierinckx A, Mazoyer S, Diaz JJ, Lachuer J, Venezia ND.

PLoS One. 2013 Jun 21;8(6):e67313. doi: 10.1371/journal.pone.0067313. Print 2013.

2.

BRCA1 interacts with poly(A)-binding protein: implication of BRCA1 in translation regulation.

Dizin E, Gressier C, Magnard C, Ray H, Décimo D, Ohlmann T, Dalla Venezia N.

J Biol Chem. 2006 Aug 25;281(34):24236-46. Epub 2006 Jun 16.

3.

Enforced expression of hsa-miR-125a-3p in breast cancer cells potentiates docetaxel sensitivity via modulation of BRCA1 signaling.

Xu X, Lv YG, Yan CY, Yi J, Ling R.

Biochem Biophys Res Commun. 2016 Oct 28;479(4):893-900. doi: 10.1016/j.bbrc.2016.09.087. Epub 2016 Sep 28.

PMID:
27693788
4.

DNA damage and eIF4G1 in breast cancer cells reprogram translation for survival and DNA repair mRNAs.

Badura M, Braunstein S, Zavadil J, Schneider RJ.

Proc Natl Acad Sci U S A. 2012 Nov 13;109(46):18767-72. doi: 10.1073/pnas.1203853109. Epub 2012 Oct 29.

5.
6.

Depletion of eIF2·GTP·Met-tRNAi translation initiation complex up-regulates BRCA1 expression in vitro and in vivo.

Aktas BH, Bordelois P, Peker S, Merajver S, Halperin JA.

Oncotarget. 2015 Mar 30;6(9):6902-14.

7.

Regulation of BRCA1 and BRCA2 expression in human breast cancer cells by DNA-damaging agents.

Andres JL, Fan S, Turkel GJ, Wang JA, Twu NF, Yuan RQ, Lamszus K, Goldberg ID, Rosen EM.

Oncogene. 1998 Apr 30;16(17):2229-41.

8.

RNA profiling reveals familial aggregation of molecular subtypes in non-BRCA1/2 breast cancer families.

Larsen MJ, Thomassen M, Tan Q, Lænkholm AV, Bak M, Sørensen KP, Andersen MK, Kruse TA, Gerdes AM.

BMC Med Genomics. 2014 Jan 31;7:9. doi: 10.1186/1755-8794-7-9.

9.
10.

Downregulation of BRCA1 protein in BCR-ABL1 leukemia cells depends on stress-triggered TIAR-mediated suppression of translation.

Podszywalow-Bartnicka P, Wolczyk M, Kusio-Kobialka M, Wolanin K, Skowronek K, Nieborowska-Skorska M, Dasgupta Y, Skorski T, Piwocka K.

Cell Cycle. 2014;13(23):3727-41. doi: 10.4161/15384101.2014.965013.

PMID:
25483082
11.

Expression of BRCA1, NBR1 and NBR2 genes in human breast cancer cells.

Dimitrov SD, Matousková E, Forejt J.

Folia Biol (Praha). 2001;47(4):120-7.

PMID:
11508855
12.

Differing effects of breast cancer 1, early onset (BRCA1) and ataxia-telangiectasia mutated (ATM) mutations on cellular responses to ionizing radiation.

Mamon HJ, Dahlberg W, Azzam EI, Nagasawa H, Muto MG, Little JB.

Int J Radiat Biol. 2003 Oct;79(10):817-29.

PMID:
14630541
13.

Estrogen coordinates translation and transcription, revealing a role for NRSF in human breast cancer cells.

Bronson MW, Hillenmeyer S, Park RW, Brodsky AS.

Mol Endocrinol. 2010 Jun;24(6):1120-35. doi: 10.1210/me.2009-0436. Epub 2010 Apr 14. Erratum in: Mol Endocrinol. 2010 Aug;24(8):1694-5.

14.

A BRCA1 deficient-like signature is enriched in breast cancer brain metastases and predicts DNA damage-induced poly (ADP-ribose) polymerase inhibitor sensitivity.

McMullin RP, Wittner BS, Yang C, Denton-Schneider BR, Hicks D, Singavarapu R, Moulis S, Lee J, Akbari MR, Narod SA, Aldape KD, Steeg PS, Ramaswamy S, Sgroi DC.

Breast Cancer Res. 2014 Mar 14;16(2):R25. doi: 10.1186/bcr3625.

15.

Progesterone induces BRCA1 mRNA decrease, cell cycle alterations and apoptosis in the MCF7 breast cancer cell line.

Ansquer Y, Legrand A, Bringuier AF, Vadrot N, Lardeux B, Mandelbrot L, Feldmann G.

Anticancer Res. 2005 Jan-Feb;25(1A):243-8.

16.

A novel crosstalk between BRCA1 and poly (ADP-ribose) polymerase 1 in breast cancer.

Li D, Bi FF, Chen NN, Cao JM, Sun WP, Zhou YM, Li CY, Yang Q.

Cell Cycle. 2014;13(21):3442-9. doi: 10.4161/15384101.2014.956507.

17.

Tumoral expression of BRCA1, estrogen receptor alpha and ID4 protein in patients with sporadic breast cancer.

Roldán G, Delgado L, Musé IM.

Cancer Biol Ther. 2006 May;5(5):505-10. Epub 2006 May 13.

PMID:
16582598
18.

miRNA expression patterns in normal breast tissue and invasive breast cancers of BRCA1 and BRCA2 germ-line mutation carriers.

Vos S, Vesuna F, Raman V, van Diest PJ, van der Groep P.

Oncotarget. 2015 Oct 13;6(31):32115-37. doi: 10.18632/oncotarget.5617.

19.

Use of DNA-damaging agents and RNA pooling to assess expression profiles associated with BRCA1 and BRCA2 mutation status in familial breast cancer patients.

Walker LC, Thompson BA, Waddell N; kConFab Investigators, Grimmond SM, Spurdle AB.

PLoS Genet. 2010 Feb 19;6(2):e1000850. doi: 10.1371/journal.pgen.1000850.

Supplemental Content

Support Center